TABLE OF CONTENTS
1 INTRODUCTION 48
1.1 OBJECTIVES OF THE STUDY 48
1.2 MARKET DEFINITION 48
1.3 OVERVIEW OF THE EUROPE BREAST CANCER DIAGNOSTIC MARKET 48
1.4 CURRENCY AND PRICING 50
1.5 LIMITATIONS 50
1.6 MARKETS COVERED 50
2 MARKET SEGMENTATION 54
2.1 MARKETS COVERED 54
2.2 GEOGRAPHICAL SCOPE 55
2.3 YEARS CONSIDERED FOR THE STUDY 56
2.4 DBMR TRIPOD DATA VALIDATION MODEL 57
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 60
2.6 MULTIVARIATE MODELLING 61
2.7 MARKET END USER COVERAGE GRID 62
2.8 TEST TYPE LIFELINE CURVE 63
2.9 DBMR MARKET POSITION GRID 64
2.10 VENDOR SHARE ANALYSIS 65
2.11 SECONDARY SOURCES 66
2.12 ASSUMPTIONS 66
3 EXECUTIVE SUMMARY 67
4 PREMIUM INSIGHTS 69
4.1 PESTEL ANALYSIS 70
4.2 PORTER'S 5 FORCES 71
5 EPIDEMIOLOGY 72
6 INDUSTRIAL INSIGHTS 73
7 REGULATORY FRAMEWORK 74
8 MARKET OVERVIEW 76
8.1 DRIVERS 78
8.1.1 LAUNCH OF TECHNOLOGICALLY ADVANCED DIAGNOSIS & THERAPEUTICS TO AID GROWTH 78
8.1.2 INCREASING PREVALENCE OF BREAST CANCER 78
8.1.3 GROWING IMPORTANCE OF WOMEN'S HEALTH 79
8.1.4 RISING AWARENESS TOWARDS THE BREAST CANCER 79
8.2 RESTRAINTS 80
8.2.1 ADVERSE EFFECTS OF BREAST CANCER THERAPEUTICS 80
8.2.2 HIGH COST OF THE IMAGING SYSTEMS 80
8.3 OPPORTUNITIES 81
8.3.1 INITIATIVES TAKEN BY THE GOVERNMENT 81
8.3.2 STRATEGIC INITIATIVES TAKEN BY THE KEY MARKET PLAYERS 81
8.3.3 GROWTH IN RESEARCH AND DEVELOPMENT OF BREAST CANCER 82
8.4 CHALLENGES 82
8.4.1 LACK OF DIAGNOSTIC INFRASTRUCTURE 82
8.4.2 LACK OF SKILLED PROFESSIONALS FOR PROPER DIAGNOSIS OF BREAST CANCER 83
9 EUROPE BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE 84
9.1 OVERVIEW 85
9.2 IMAGING 88
9.2.1 IONIZING BREAST IMAGING TECHNOLOGIES 89
9.2.1.1 FULL-FIELD DIGITAL MAMMOGRAPHY (FFDM) 90
9.2.1.2 ANALOG MAMMOGRAPHY 90
9.2.1.3 3D BREAST TOMOSYNTHESIS 90
9.2.1.4 POSITRON EMISSION TOMOGRAPHY/ COMPUTED TOMOGRAPHY (PET/CT) 90
9.2.1.5 MOLECULAR BREAST IMAGING/ BREAST SPECIFIC GAMMA IMAGING (MBI/BSMI) 90
9.2.1.6 POSITRON EMISSION MAMMOGRAPHY 90
9.2.1.7 OTHERS 90
9.2.2 NON-IONIZING IMAGING TECHNOLOGIES 90
9.2.2.1 OPTICAL IMAGING 91
9.2.2.2 BREAST ULTRASOUND 91
9.2.2.3 BREAST MRI (MAGNETIC RESONANCE IMAGING) 91
9.2.2.4 AUTOMATED WHOLE BREAST ULTRASOUND (AWBU) 91
9.2.2.5 BREAST THERMOGRAPHY 92
9.2.3 BIOPSY 92
9.2.3.1 SURGICAL BIOPSY 93
9.2.3.2 FINE NEEDLE ASPIRATION BIOPSY 93
9.2.3.3 CORE NEEDLE BIOPSY 93
9.2.3.4 IMAGE-GUIDED BIOPSY 93
9.2.3.5 SENTINEL LYMPH NODE BIOPSY 94
9.2.4 GENOMIC TEST 94
9.2.4.1 MOLECULAR TESTING 95
9.2.4.1.1 PD-L1 96
9.2.4.1.2 MICROSATELLITE INSTABILITY-HIGH (MSI-H) OR DNA MISMATCH REPAIR DEFICIENCY (DMMR) 96
9.2.4.1.3 NTRK GENE FUSIONS 96
9.2.4.1.4 PI3KCA GENE MUTATION 96
9.2.4.2 MAMMAPRINT 96
9.2.4.3 ONCOTYPE DX 96
9.2.4.4 OTHERS 96
9.3 BLOOD TEST 97
9.4 OTHERS 98
10 EUROPE BREAST CANCER DIAGNOSTICS MARKET, BY TYPE 99
10.1 OVERVIEW 100
10.2 INVASIVE DUCTAL CARCINOMA 103
10.3 DUCTAL CARCINOMA IN SITU 103
10.4 INFLAMMATORY BREAST CANCER 104
10.5 METASTATIC BREAST CANCER 105
11 EUROPE BREAST CANCER DIAGNOSTICS MARKET, BY END USER 106
11.1 OVERVIEW 107
11.2 HOSPITALS 109
11.3 DIAGNOSTICS CENTERS 110
11.4 CLINICS 111
11.5 RESEARCH & ACADEMIC INSTITUTES 111
11.6 OTHERS 112
12 EUROPE BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 114
12.1 OVERVIEW 115
12.2 DIRECT TENDER 118
12.3 RETAIL SALES 118
12.4 OTHERS 119
13 EUROPE BREAST CANCER DIAGNOSTICS MARKET, BY REGION 120
13.1 EUROPE 121
13.1.1 GERMANY 130
13.1.2 FRANCE 136
13.1.3 RUSSIA 142
13.1.4 ITALY 148
13.1.5 U.K. 154
13.1.6 SPAIN 160
13.1.7 TURKEY 166
13.1.8 NETHERLANDS 172
13.1.9 BELGIUM 178
13.1.10 SWITZERLAND 184
13.1.11 IRELAND 190
13.1.12 REST OF EUROPE 196
14 EUROPE BREAST CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE 197
14.1 COMPANY SHARE ANALYSIS: EUROPE 197
15 SWOT ANALYSIS 198
16 COMPANY PROFILE 199
16.1 HOLOGIC, INC. 199
16.1.1 COMPANY SNAPSHOT 199
16.1.2 REVENUE ANALYSIS 199
16.1.3 COMPANY SHARE ANALYSIS 200
16.1.4 PRODUCT PORTFOLIO 200
16.1.5 RECENT DEVELOPMENTS 201
16.2 SIEMENS HEALTHCARE GMBH 202
16.2.1 COMPANY SNAPSHOT 202
16.2.2 REVENUE ANALYSIS 203
16.2.3 COMPANY SHARE ANALYSIS 203
16.2.4 PRODUCT PORTFOLIO 204
16.2.5 RECENT DEVELOPMENTS 204
16.3 F. HOFFMANN- LA ROCHE LTD 205
16.3.1 COMPANY SNAPSHOT 205
16.3.2 REVENUE ANALYSIS 205
16.3.3 COMPANY SHARE ANALYSIS 206
16.3.4 PRODUCT PORTFOLIO 206
16.3.5 RECENT DEVELOPMENTS 207
16.4 KONINKLIJKE PHILIPS N.V. 208
16.4.1 COMPANY SNAPSHOT 208
16.4.2 REVENUE ANALYSIS 208
16.4.3 COMPANY SHARE ANALYSIS 209
16.4.4 PRODUCT PORTFOLIO 209
16.4.5 RECENT DEVELOPMENTS 210
16.5 ABBOTT 211
16.5.1 COMPANY SNAPSHOT 211
16.5.2 REVENUE ANALYSIS 211
16.5.3 COMPANY SHARE ANALYSIS 212
16.5.4 PRODUCT PORTFOLIO 212
16.5.5 RECENT DEVELOPMENTS 212
16.6 ABACUS ALS 213
16.6.1 COMPANY SNAPSHOT 213
16.6.2 PRODUCT PORTFOLIO 213
16.6.3 RECENT DEVELOPMENTS 213
16.7 BD 214
16.7.1 COMPANY SNAPSHOT 214
16.7.2 REVENUE ANALYSIS 214
16.7.3 COMPANY SHARE ANALYSIS 215
16.7.4 PRODUCT PORTFOLIO 215
16.7.5 RECENT DEVELOPMENTS 215
16.8 BIOCEPT, INC. 216
16.8.1 COMPANY SNAPSHOT 216
16.8.2 REVENUE ANALYSIS 216
16.8.3 PRODUCT PORTFOLIO 217
16.8.4 RECENT DEVELOPMENTS 217
16.9 BIOMRIEUX 218
16.9.1 COMPANY SNAPSHOT 218
16.9.2 REVENUE ANALYSIS 218
16.9.3 PRODUCT PORTFOLIO 219
16.9.4 RECENT DEVELOPMENTS 219
16.10 BIO-RAD LABORATORIES, INC. 220
16.10.1 COMPANY SNAPSHOT 220
16.10.2 REVENUE ANALYSIS 220
16.10.3 PRODUCT PORTFOLIO 221
16.10.4 RECENT DEVELOPMENT 221
16.11 CEPHEID 222
16.11.1 COMPANY SNAPSHOT 222
16.11.2 REVENUE ANALYSIS 222
16.11.3 PRODUCT PORTFOLIO 223
16.11.4 RECENT DEVELOPMENT 223
16.12 EXACT SCIENCES CORPORATION 224
16.12.1 COMPANY SNAPSHOT 224
16.12.2 REVENUE ANALYSIS 224
16.12.3 COMPANY SHARE ANALYSIS 225
16.12.4 PRODUCT PORTFOLIO 225
16.12.5 RECENT DEVELOPMENTS 226
16.13 FUJIFILM CORPORATION 227
16.13.1 COMPANY SNAPSHOT 227
16.13.2 REVENUE ANALYSIS 227
16.13.3 PRODUCT PORTFOLIO 228
16.13.4 RECENT DEVELOPMENT 228
16.14 GENERAL ELECTRIC 229
16.14.1 COMPANY SNAPSHOT 229
16.14.2 REVENUE ANALYSIS 229
16.14.3 PRODUCT PORTFOLIO 230
16.14.4 RECENT DEVELOPMENTS 230
16.15 ILLUMINA, INC. 231
16.15.1 COMPANY SNAPSHOT 231
16.15.2 REVENUE ANALYSIS 231
16.15.3 PRODUCT PORTFOLIO 232
16.15.4 RECENT DEVELOPMENTS 232
16.16 MYRIAD GENETICS, INC. 233
16.16.1 COMPANY SNAPSHOT 233
16.16.2 REVENUE ANALYSIS 233
16.16.3 PRODUCT PORTFOLIO 234
16.16.4 RECENT DEVELOPMENT 234
16.17 NANOSTRING. 235
16.17.1 COMPANY SNAPSHOT 235
16.17.2 REVENUE ANALYSIS 235
16.17.3 PRODUCT PORTFOLIO 236
16.17.4 RECENT DEVELOPMENT 236
16.17.5 RECENT DEVELOPMENT 236
16.18 ONCOSTEM. 237
16.18.1 COMPANY SNAPSHOT 237
16.18.2 PRODUCT PORTFOLIO 237
16.18.3 RECENT DEVELOPMENT 237
16.19 PROVISTA DIAGNOSTICS. 238
16.19.1 COMPANY SNAPSHOT 238
16.19.2 PRODUCT PORTFOLIO 238
16.19.3 RECENT DEVELOPMENT 238
16.20 THERMO FISHER SCIENTIFIC INC. 239
16.20.1 COMPANY SNAPSHOT 239
16.20.2 REVENUE ANALYSIS 239
16.20.3 PRODUCT PORTFOLIO 240
16.20.4 RECENT DEVELOPMENT 240
17 QUESTIONNAIRE 241
18 RELATED REPORTS 244

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.